Valrubicin

Drug Profile

Valrubicin

Alternative Names: AD 32; N-Trifluoroacetyladriamycin-14-valerate; NSC 246131; Valstar; Valtaxin

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Anthra Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Anthracyclines; Antineoplastics; Cytostatics; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bladder cancer
  • Discontinued Endometrial cancer; Ovarian cancer

Most Recent Events

  • 24 Jul 2012 CTP alert for NCT01606345 - Endo Pharma is only the collaborator - not added
  • 14 Feb 2012 Endo Pharmaceuticals terminates a phase III trial in Bladder cancer in USA (NCT01310803)
  • 18 Jul 2011 Endo Pharmaceuticals initiates enrolment in a phase III trial for Bladder cancer in USA (NCT01310803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top